{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}],"title":"Percentage of participants positive for ADA at Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"}]}],"title":"Percentage of participants positive for ADA Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"}],"units":"Participants"}],"groups":[{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Anti-Drug Antibody (ADA) population:\n\n* Baseline ADA-evaluable population: all participants with at least one evaluable ADA assay result from a baseline sample\n* Post baseline ADA-Evaluable population: all participants with at least one evaluable ADA assay result from at least one post-baseline sample.\n\nFor all safety, PK and immunogenicity analyses, participants were grouped according to the treatment actually received, including cases in which atezolizumab was received in error.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hours) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16, and at every 8 cycles thereafter until TD, at TD, and at 90-150 days after TD (maximum up to 45 months) (1 Cycle = 28 days)","title":"Percentage of Participants With Anti-Drug Antibodies' (ADAs) Against Atezolizumab in ADA Evaluable Population","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}